Abstract
Nanocarriers are effective non-viral vectors for drug and gene delivery with low immunogenicity in comparison with viral vectors. However, the lack of organ or cell specificity sometimes hinders their application and brings about unexpected side effects. Active targeting is an outstanding strategy recently developed for drug delivery systems, for example, surface modification of nanocarriers with specific ligands could target the pathological area to provide the maximum therapeutic efficacy. In such cases, the characteristics of the ligands determine the active targeting abilities of the nanocarrier systems. Recently, more attentions have been paid to saccharides as ligands for saccharidemodified nanocarriers, possesing the receptor-mediated targeting properties and showing the potential for cell-specific delivery of drugs and genes. In this review, various kinds of glycosylated nanocarriers are discussed, including: varying ligands, targeting properties, therapeutic effects, and methods for administering the nanocarriers. The advantages as well as the probable associated drawbacks of these vectors are communicated.
Keywords: Nanocarriers, surface modification, saccharide ligands, active targeting, drug and gene delivery
Current Pharmaceutical Design
Title: Saccharide Modified Pharmaceutical Nanocarriers for Targeted Drug and Gene Delivery
Volume: 15 Issue: 32
Author(s): Wangyang Yu, Na Zhang and Changjun Li
Affiliation:
Keywords: Nanocarriers, surface modification, saccharide ligands, active targeting, drug and gene delivery
Abstract: Nanocarriers are effective non-viral vectors for drug and gene delivery with low immunogenicity in comparison with viral vectors. However, the lack of organ or cell specificity sometimes hinders their application and brings about unexpected side effects. Active targeting is an outstanding strategy recently developed for drug delivery systems, for example, surface modification of nanocarriers with specific ligands could target the pathological area to provide the maximum therapeutic efficacy. In such cases, the characteristics of the ligands determine the active targeting abilities of the nanocarrier systems. Recently, more attentions have been paid to saccharides as ligands for saccharidemodified nanocarriers, possesing the receptor-mediated targeting properties and showing the potential for cell-specific delivery of drugs and genes. In this review, various kinds of glycosylated nanocarriers are discussed, including: varying ligands, targeting properties, therapeutic effects, and methods for administering the nanocarriers. The advantages as well as the probable associated drawbacks of these vectors are communicated.
Export Options
About this article
Cite this article as:
Yu Wangyang, Zhang Na and Li Changjun, Saccharide Modified Pharmaceutical Nanocarriers for Targeted Drug and Gene Delivery, Current Pharmaceutical Design 2009; 15 (32) . https://dx.doi.org/10.2174/138161209789649547
DOI https://dx.doi.org/10.2174/138161209789649547 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histopathology of Connective Tissue Disease-Associated Pleuropulmonary Disease
Current Respiratory Medicine Reviews Patents in Targets and Drugs for Unbalanced Cytokine and Chemokine Network Mediated Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets MCC950 Reduces Neuronal Apoptosis in Spinal Cord Injury in Mice
CNS & Neurological Disorders - Drug Targets Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Remote Ischemic Conditioning Improves Cognitive Function During Cerebral Vascular Injury Through the Induction of Autophagy
Current Neurovascular Research Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Therapeutic Potential of Ferulic Acid in Alzheimer's Disease
Current Drug Delivery Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options
Current Respiratory Medicine Reviews Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Current Pharmaceutical Design Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews